THE FUSE

I have a habit of jumping toward the next promising thing the moment I hear about it. That is what happened when psychedelics started making their way back into clinical conversation, this time with serious money behind them, rigorous protocols, and trials designed to convince regulatory agencies that these compounds deserved a second look. Posttraumatic stress disorder (PTSD) was at the center of it. I went immediately to get trained, had my own experiences, and came away convinced that the benefits were real, and that what made them real was not the substance alone but everything surrounding it.